Impact of primary kidney disease on the effects of empagliflozin in patients with chronic kidney disease: secondary analyses of the EMPA-KIDNEY trial (2024)

First Author: Judge P

Attributed to: Adiposity and kidney disease: observations from large blood-based prospective cohorts across a wide range of different populations funded by MRC

No abstract provided

Type: Journal Article/Review

Parent Publication: The Lancet Diabetes & Endocrinology

Issue: 1